Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment response and safety of immunotherapy for advanced non-small cell lung cancer with comorbid chronic obstructive pulmonary disease: a retrospective cohort study.
Zhang K, Zhou C, Gao J, Yu P, Lin X, Xie X, Liu M, Zhang J, Xie Z, Cui F, Li S, Passiglia F, Stella GM, Qin Y. Zhang K, et al. Among authors: passiglia f. Transl Lung Cancer Res. 2022 Nov;11(11):2306-2317. doi: 10.21037/tlcr-22-667. Transl Lung Cancer Res. 2022. PMID: 36519030 Free PMC article.
Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Anobile DP, Salaroglio IC, Tabbò F, La Vecchia S, Akman M, Napoli F, Bungaro M, Benso F, Aldieri E, Bironzo P, Kopecka J, Passiglia F, Righi L, Novello S, Scagliotti GV, Riganti C. Anobile DP, et al. Among authors: passiglia f. Clin Cancer Res. 2023 Oct 2;29(19):3958-3973. doi: 10.1158/1078-0432.CCR-22-3949. Clin Cancer Res. 2023. PMID: 37285115
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.
Bronte G, Rolfo C, Giovannetti E, Cicero G, Pauwels P, Passiglia F, Castiglia M, Rizzo S, Vullo FL, Fiorentino E, Van Meerbeeck J, Russo A. Bronte G, et al. Among authors: passiglia f. Crit Rev Oncol Hematol. 2014 Feb;89(2):300-13. doi: 10.1016/j.critrevonc.2013.08.003. Epub 2013 Aug 28. Crit Rev Oncol Hematol. 2014. PMID: 24041630
Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations.
Fanale D, Iovanna JL, Calvo EL, Berthezene P, Belleau P, Dagorn JC, Ancona C, Catania G, D'Alia P, Galvano A, Gulotta E, Lo Dico S, Passiglia F, Bronte G, Midiri M, Lo Re G, Cicero G, Bazan V, Russo A. Fanale D, et al. Among authors: passiglia f. Oncology. 2013;85(5):306-11. doi: 10.1159/000354737. Epub 2013 Nov 9. Oncology. 2013. PMID: 24217364
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.
Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R. Rolfo C, et al. Among authors: passiglia f. Cancer Treat Rev. 2014 Sep;40(8):990-1004. doi: 10.1016/j.ctrv.2014.05.009. Epub 2014 Jun 6. Cancer Treat Rev. 2014. PMID: 24953979 Free article. Review.
The role of targeted therapy for gastrointestinal tumors.
Rolfo C, Bronte G, Sortino G, Papadimitriou K, Passiglia F, Fiorentino E, Marogy G, Russo A, Peeters M. Rolfo C, et al. Among authors: passiglia f. Expert Rev Gastroenterol Hepatol. 2014 Nov;8(8):875-85. doi: 10.1586/17474124.2014.922870. Epub 2014 Jun 24. Expert Rev Gastroenterol Hepatol. 2014. PMID: 24957206 Review.
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?
Rolfo C, Sortino G, Smits E, Passiglia F, Bronte G, Castiglia M, Russo A, Santos ES, Janssens A, Pauwels P, Raez L. Rolfo C, et al. Among authors: passiglia f. Expert Rev Anticancer Ther. 2014 Oct;14(10):1173-87. doi: 10.1586/14737140.2014.952287. Epub 2014 Aug 22. Expert Rev Anticancer Ther. 2014. PMID: 25148289 Review.
121 results